Synchron Inc, a rival to Elon Musk’s Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company’s chief executive told Reuters.
Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview.
Synchron Inc, a rival to Elon Musk’s Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company’s chief executive told Reuters.
Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview.
“Part of this registry is to start to enable local physicians to speak to patients with motor impairment,” he said. “There’s a lot of interest so we don’t want it to come in a big bottleneck right before the study we’ll be doing.”
New-York based Synchron is farther along in the process of testing its brain implant than Neuralink. Both companies initially aim to help paralyzed patients type on a computer using devices that interpret brain signals.
Synchron received U.S. authorization for preliminary testing in July 2021 and has implanted its device in six patients. Prior testing in four patients in Australia showed no serious adverse side effects, the company has reported.
Synchron will be analyzing the U.S. data to prepare for the larger study, while awaiting authorization from the U.S. Food and Drug Administration to proceed, Oxley said. Synchron and the FDA declined to comment on the expected timing of that decision.
The company aims to include patients who are paralyzed due to the neurodegenerative disease ALS (amyotrophic lateral sclerosis), stroke and multiple sclerosis, Oxley said.
Mount Sinai in New York, the University at Buffalo Neurosurgery and the University of Pittsburgh Medical Center (UPMC) are collaborating on the preliminary study. Synchron said it hopes to involve these centers in the larger trial.
